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ABSTRACT

Role of Macrophage Apoptosis in Atherosclerosis
by
June Liu
The presence of apoptotic cells in atherosclerotic lesions has been broadly reported in the
past 10 years. The majority of these apoptotic cells are macrophages. However, the
pathogenic role of macrophage apoptosis in the development of atherosclerosis remains
to be elucidated. Elevated expression of Bax, one of the pivotal pro-apoptotic proteins of
the Bcl-2 family, has been found in human atherosclerotic plaques. Activation of Bax also
occurs in free cholesterol-loaded and oxysterol treated mouse macrophages. In this study,
we evaluated the influence of Bax deficiency on apoptosis in macrophage-like P388D1
cells by using small interfering RNA (siRNA) to suppress Bax expression, as well as in
peritoneal macrophages isolated from Bax null mice (Bax-/-). Apoptotic activities in both
cell types deficient for Bax were significantly reduced compared to that in control cells. To
examine the effect of macrophage Bax deficiency on the development of atherosclerosis,
fourteen 8-week-old male LDL-receptor null (LDLR-/-) mice were lethally irradiated and
reconstituted with either wild type (WT) C57BL6 or Bax-/- bone marrow. Three weeks
later, the mice were challenged with a Western diet for 10 weeks. No differences were
found in the plasma cholesterol level between the WT and Bax-/- group. However,
quantitation of cross sections from proximal aortas revealed a 49.2% increase (P=0.0259)
in the mean lesion area of the Bax-/- group compared to the WT group. A 53% decrease
in apoptotic macrophages in the Bax-/- group was found by TUNEL staining (P<0.05). In
conclusion, Bax deficiency produces a reduction of apoptotic activity in macrophages and
is associated with the accelerated atherosclerosis in LDLR null mice fed a Western diet.
These results strongly support our hypothesis that macrophage apoptosis suppresses the
development of atherosclerosis.
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CHAPTER 1
INTRODUCTION

Apoptosis

Within each cell lineage, the control of cell number is determined by the balance
between cell proliferation and cell death. Biologists are now beginning to appreciate that
the regulation of cell death is just as complex as the regulation of cell proliferation.
Apoptosis (also called programmed cell death), characterized by cell shrinkage,
membrane blebbing, DNA fragmentation, and nuclear condensation, plays a critical role
in tissue development and maintenance of homeostasis within multi-cellular organisms.
When activated, this suicide program allows for the elimination of cells that have been
produced in excess, that have developed improperly, or that have sustained genetic
damage.
Apoptotic cell death can be distinguished from necrotic cell death (Wyllie and others
1980; Raff 1992). Necrotic cell death is a pathologic form of cell death resulting from
acute cellular injury, and is typified by an influx of water and extracellular ions, leading to
rapid cell swelling and lysis. Due to the ultimate breakdown of the plasma membrane, the
cytoplasmic contents including lysosomal enzymes are released into the extracellular
environment. Therefore, in vivo, necrotic cell death is often associated with extensive
tissue damage resulting in an intense inflammatory response. Apoptosis, on the other
hand, can be triggered by a variety of extrinsic and intrinsic signals, generating
completely opposite morphology. The apoptotic cell maintains its plasma membrane
integrity. However, alterations in the plasma membrane of apoptotic cells signal
neighboring phagocytic cells to engulf them and thus to complete the degradation
process (Ellis and others 1991). Cells not immediately phagocytosed break down into
9

smaller membrane-bound fragments called apoptotic bodies, which will be digested by
phagocytic cells eventually. An important feature of apoptosis is that it results in the
elimination of the dying cell without induction of an inflammatory response.

Caspase
One key to understanding apoptosis is the activation and function of a set of
proteinases, the caspases. Caspases belong to a family of cysteine proteases that
selectively cleave proteins at sites just C-terminal to aspartate residues. Numerous
caspases have been discovered and each has been given a variety of names: caspase-1
(ICE), caspase-2 (ICH-1, Nedd-2), caspase-3 (CPP32, Yama, apopain), caspase-4 (TX,
ICH-2, ICErel-II, also homologous to murine caspase-11), caspase-5 (ICErel-III, TY),
caspase-6 (Mch-2), caspase-7 (Mch-3, ICE-LAP, CMH-1), caspase-8 (MACH, FLICE,
Mch-5), caspase-9 (Apaf-3, ICE-LAP6, Mch-6), caspase-10 (Mch-4), caspase-13
(ERICE), and caspase-14 (MICE) (Chang and Yang 2000).
Normally, caspases reside in cells as inactive proforms, and can be activated by
proteolytic cleavage in two different ways. Caspases can be broadly catagorized as either
“initiator” caspases (caspase 8, 9, etc.) or “executioner” caspases (caspase 3, 6, 7, etc.).
Initiator caspases play a role in the amplification of an apoptotic signal by cleaving and
activating other initator caspases, which in turn, cleave and activate the executioner
caspases. This is the major way of activating executioner caspases. Another way to
activate an executioner caspase is through the action of adaptor proteins, such as Apaf-1
and FADD, which bind to the prodomains of the initiator caspases. Binding of the adaptor
protein promotes the activation of the initiator caspases, which can then go on to cleave
and activate the executioner caspases. The executioner caspases have specific
intracellular targets such as proteins of the nuclear lamina and cytoskeleton (Porter and
Janicke 1999). Cleavage of these substrates leads to the demise of the cell.
10

Two Major Apoptotic Pathways in Mammalian Cells
Two basic pathways for apoptosis have been described, the death receptor pathway
and the mitochondrial pathway (Gross and others 1999; Hengartner 2000). In the death
receptor pathway, extrinsic signals, such as Fas ligand and tumor necrosis factor (TNF),
bind to their receptors, Fas or TNF receptor on the plasma membrane, forming
membrane-bound signaling complexes. These complexes then recruit, through adapter
proteins, procaspase 8 molecules, resulting in a relatively high local concentration of
zymogen. Self or mutual cleavage of procaspase 8 leads to the activation of caspse 8,
which then further activates the death executioner protease - caspase 3.
In the mitochondrial apoptosis pathway, intrinsic signals such as DNA damage caused
by UV radiation, stress caused by oxidants or growth factor withdrawal, can induce the
mitochondrial dysfunction and release of cytochrome c from the intermembrane space
through the combined regulation of Bcl-2 family members on the mitochondrial
membrane. The detailed mechanism regulating cytochrome c release remains to be
elucidated. Released cytochrome c activates Apaf-1, which in turn activates caspase 9.
The apoptosome, a complex consisting of cytochrome c, Apaf-1, and caspase 9, then
activates the common death executor – caspase 3.
The cross-talk between the two apoptotic pathways is mediated by another Bcl-2
family member, Bid (Luo and others 1998). Activated caspase 8 in the death receptor
pathway can cause the cleavage of Bid. The C-terminal part of Bid, also called truncated
Bid, will then translocate to the mitochondria where it stimulates the cytochrome c release
(Fig 1).
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Figure 1 Two major apoptotic pathways in mammalian cells (Adapted from: Hengartner
MO. The biochemistry of apoptosis. Nature 2000;407:770-776)

Bcl-2 Family
The Bcl-2 family members focus much of their effects at the level of mitochondria and
play pivotal roles in deciding the fate of a cell (Gross and others 1999). Based on their
intracellular functions, Bcl-2 family proteins can be divided into two opposite subtypes:
anti-apoptotic proteins such as Bcl-2 and Bcl-xL, and pro-apoptotic proteins such as Bax
and Bak. Indeed, the ratio between these two subsets determines, at least in part, the
susceptibility of cells to a death signal (Oltvai and others 1993).
Bcl-2 family members have four conserved Bcl-2 homology (BH) domains designated
BH1, BH2, BH3, and BH4. Many of the anti-apoptotic members display sequence
12

conservation in all four domains. However, many pro-apoptotic members, so-called
BH3-domain-only members, have sequence homology only in the BH3 domain. To date,
all the BH3-domain-only members are pro-apoptotic, suggesting a critical death function
of the BH3 domain. Multidomain pro-apoptotic members, such as Bax and Bak, have
sequence homology in BH1, BH2, as well as BH3 (Fig 2).

Anti-apoptotic
BH4

BH3

BH1

BH2

TM

Bcl-2 / Bcl-xL
Pro-apoptotic
Bax / Bak
Bid / Bad
Figure 2 Structures of representative Bcl-2 family members. TM: terminal hydrophobic
domain. (Modified from Hengartner MO. The biochemistry of apoptosis. Nature
2000;407:770-776)

Two major anti-apoptotic proteins in the family, Bcl-2 and Bcl-xL, normally reside in the
mitochondrial membrane. Over-expression of Bcl-2 in a variety of cells protects them from
different death stimuli ( Vaux and others 1988; McDonnell and others 1989; Sentman and
others 1991). Bcl-xL deficiency leads to massive cell death of immature hematopoietic
cells in mice (Motoyama and others 1995).
Among pro-apoptotic members, Bak has been reported to be a membrane protein
localized in the mitochondrial membrane (Griffiths and others 1999). Controversy remains
in terms of the subcellular localization of Bax due to lack of direct evidence. One
hypothesis is that in healthy cells, Bax is predominantly a cytosolic monomer. Upon
13

stimulation, it undergoes conformational changes, translocates to the outer mitochondrial
membrane or endoplasmic reticulum (ER) where it forms homodimers (Hsu and others
1997; Antonsson and others 2001; Zong and others 2003). However, it remains unclear
whether the dimerization of Bax occurs in the cytosol or is coincident with membrane
insertion. An alternative hypothesis is that formation of heterodimers of Bax and Bcl-2 in
the mitochondrial membrane prevents cell death under normal growth conditions (Oltvai
and others 1993; Yin and others 1994). In the presence of survival factors,
phosphorylation of Bad, one of the BH3-domain only pro-apoptotic proteins, by
Akt/protein kinase B results in the binding of phosphorylated Bad to protein 14-3-3 in the
cytosol. In the absence of survivial factors, dephosphorylation of Bad leads to the
heterodimerization of Bad with Bcl-2 or Bcl-xL on the mitochondrial membrane, and
displaces Bax ( Yang and others 1995a; Zha and others 1996; Datta and others 2002;
Won and others 2003), which will then form homodimers on the mitochondrial membrane.
Despite of the controversy, the ultimate function of pro-apoptotic proteins Bax or Bak
is that they permeabilize the outer mitochondrial membrane, allowing the efflux of
cytochrome c and other apoptosis regulatory proteins into the cytosol (Manon and others
1997; Gross and others 1999; Martinou and Green 2001). The presence of excessive
Bcl-2 or Bcl-xL can inhibit the activation of Bax following a death signal (Gross and others
1998). Expression of the multidomain pro-apoptotic proteins, Bax and/or Bak, are
required for the activity of the mitochondrial apoptosis pathway (Wei and others 2001).
Suggestive of the central physiological role for Bax in programmed cell death, Bak null
mice fail to show any developmental defects (Lindsten and others 2000); however Bax
deficient mice displayed hyperplasia of thymocytes and B cells as well as abnormalities in
14

the development of the reproductive system (Knudson and others 1995). When Bak
deficient mice were mated to Bax deficient mice to create double knockout mice, the
majority of Bax-/-Bak-/- mice died perinatally with fewer than 10% surviving into
adulthood. The surviving Bax-/-Bak-/- mice displayed multiple developmental defects
such as persistence of interdigital webs, and accumulation of excess cells with both the
central nervous and hematopoietic systems. Mouse lymphocytes deficient in both Bax
and Bak were resistant to death induced by growth factor withdrawal (Lindsten and others
2000). Bax-/-Bak-/- mouse embryonic fibroblasts have also been shown to be resistant to
multiple apoptotic stimuli that act through disruption of mitochondrial function:
staurosporine, UV radiation, growth factor deprivation, and the ER stress stimuli
thapsigargin and tunicamycin (Wei and others 2001). Thus, Bax and Bak have
overlapping roles in the regulation of apoptosis during mammalian development and
tissue homeostasis, and the activation of Bax or Bak appears to be an essential gateway
to mitochondrial dysfunction in apoptosis (Wei and others 2001; Zong and others 2003).
Most recently, a large body of research has been directed to the regulation of ER Ca2+,
the main intracellular Ca2+ storage, by Bcl-2 family members (Nutt and others 2002;
Scorrano and others 2003; Zong and others 2003). Alterations in intracellular Ca2+
homeostasis have been implicated in the control of apoptosis. Depletion of the ER Ca2+
pool has been believed to be an early event in apoptosis (Liu and others 1996; McConkey
and Orrenius 1997). Close contacts exist between mitochondrial and the sites of ER Ca2+
release, so that ER Ca2+ release leads to rapid Ca2+ accumulation in mitochondria
(Rizzuto and others 1998; Csordas and others 1999). Mitochondral Ca2+ uptake promotes
cytochrome c release in cells exposed to the proapoptotic agent staurosporine (Szalai
15

and others 1999; Pacher and Hajnoczky 2001). Bcl-2 has been shown to regulate both
the mitochondrial and ER Ca2+ homestasis (Murphy and others 1996; Foyouzi-Youssefi
and others 2000), and prevents Ca2+ -induced cytochrome c release (Shimizu and others
1998). Overexpression of Bcl-2 protects cells from death induced by thapsigargin, an
irreversible inhibitor of the sarcoplasmic-ER Ca2+ adenosine triphosphatase pump
(SERCA) responsible for the uptake of Ca2+ from the cytosol into the ER lumen (Lam and
others 1994). On the other hand, Bax and Bak have also been believed to localize to the
ER. By increasing the ER Ca2+ load and Ca2+ transfer from ER to mitochondria, Bax and
Bak control another check-point for apoptosis (Breckenridge and others 2003; Oakes and
others 2003). A detailed mechanism for the regulation of ER Ca2+ by Bcl-2 family
members has yet to be elucidated.

Apoptosis in Development and Pathogenesis of Diseases
The fundamental roles of apoptosis in mammalian development have been well
described from the formation of the inner and outer cell mass in the blastocyst to the
ongoing cell death in adulthood that maintains homeostasis of cell number by balancing
mitotic cell production (Coucouvanis and Martin 1995; Brison and Schultz 1997). It is
broadly involved in the formation of tubes, the separation of the digits, the remodeling of
bone, and the involution of the mammary glands. In the haemopoietic system, the excess
cells at each stage of development are culled by apoptosis. In the thymus, cells that fail to
correctly rearrange their antigen receptors are also removed by apoptosis (Nossal 1994).
Failure of cells to undergo apoptosis is involved in the pathogenesis of a variety of
human diseases, including cancer, autoimmune disease, and certain viral infections,
which are all characterized by the excessive accumulation of cells (Williams and others
16

1990; Raff and others 1993; Hoffman and Liebermann 1994). For example, the p53 gene
product is required for cells to initiate apoptosis in response to genotoxic damage (Lowe
and others 1993). Deficiency of p53 in tumors, such as fibrosarcoma, underlies the
enhanced resistance to chemotherapeutic agents and radiation (Lowe and others 1994).
The Bcl-2 gene was first discovered in most human follicular lymphomas (Bakhshi and
others 1985; Tsujimoto and others 1985). Initially viewed as an oncogene, Bcl-2
overexpression prevents cells from initiating apoptosis in response to a number of stimuli
(Vaux and others 1988; Hockenbery and others 1990).
Failure to remove autoimmune cells that arise during development or that develop as
a result of somatic mutation during an immune response can result in autoimmune
disease. For example, cell surface receptor Fas, a member of the TNF receptor family, is
critical in regulating cell death in lymphocytes. Mutations in the Fas receptor and in the
Fas ligand have been reported to attribute to two forms of hereditary autoimmune disease
(Suda and others 1993).
In viral infection, the disruption of cell physiology can cause an infected cell to undergo
apoptosis. A number of viruses have developed mechanisms to disrupt the normal
regulation of apoptosis within the infected cell. For example, an effective adenoviral
infection depends on the function of the E1B 19-kD protein (Rao and others 1992). The
E1B protein has been shown to block apoptosis directly, and its function can be replaced
in adenovirus by Bcl-2.
In addition, an accelerated rate of cell death may play a role in the progression of a
large number of diseases characterized by cell loss, such as neurodegenerative
disorders, AIDS, and osteoporosis. A wide variety of neurological diseases, such as
Alzheimer’s disease, Parkinson’s disease, and various forms of cerebellar degeneration
that are characterized by the gradual loss of specific sites of neurons may also have an
apoptotic component in their pathologies (Heintz 1993; Isacson 1993). In these diseases,
17

excessive cell death results in specific disorders of movement and central nervous
system function. Oxidative stress, calcium toxicity, mitochondrial defects, excitatory
toxicity, and deficiency of survival factors have all been postulated to contribute to the
pathogenesis of these disorders (Choi 1992). Each of these pathways predisposes
neurons to apoptosis, either in vitro or in vivo.

Plasma Lipoproteins

Plasma lipoproteins are the primary carriers of lipids in the circulation. Lipoproteins
can be divided into six major classes and two specialized classes. Four of the major
classes of lipoproteins — very low density lipoprotein (VLDL), intermediate density
lipoprotein (IDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) — are
derived from the liver and are present in plasma from both fasted and nonfasted subjects.
The other two major classes — chylomicrons and chylomicron remnants — are derived
from the small intestine and are found in the plasma only after a fatty meal. Like LDL, the
specialized classes of lipoproteins, β-VLDL and lipoprotein(a), are significant because
they are positively correlated with coronary heart disease and atherosclerosis.
Due to the distinct compositions of different percentages of lipids and proteins,
lipoproteins can be separated by sequential ultracentrifugation using salt solutions with
increasing densities. Lipoproteins with a greater proportion of lipids, especially neutral
lipids (triglycerides and cholesteryl esters), are less dense and float at a lower density
layer upon ultracentrifugation. For example, VLDLs float to the top of the tube when
plasma is ultracentrifuged. After the VLDL is removed, the remaining is raised to d =
1.019 g/ml with salt and the ultracentrifugation is repeated to isolate IDL. The same
18

process is repeated to isolate LDL and HDL. The density of lipoprotein particles is also
inversely related to their size (Table 1).

Table 1 Characteristics of human plasma lipoproteins
Lipoprotein

Density (g/ml)

Diameter (Å)

Apoproteins

Major lipids

VLDL

< 1.006

300 – 700

B-100, E, C

Triglycerides

IDL

1.006 - 1.019

LDL

1.019 - 1.063

200

B-100

HDL

1.063 - 1.21

80 – 130

A-I, A-II, C

Chylomicron

< 0.95

> 1,000

B-48, E, A, C

<0.95

> 1,000

B-48, E

Chylomicron
Remnant

B-100, E

Cholesterol,
triglycerides
Cholesterol
Phospholipid,
cholesterol
Triglycerides
Cholesterol,
triglycerides

(Modified from Thomas L. Innerarity. 1991. Plasma Lipoproteins. In: Encyclopedia of
Human Biology, Volume 6. Academic Press, Inc. p 23-35.)
LDL and LDL Receptor (LDLR)
LDL, the end product of the lipolysis of VLDL and IDL by lipoprotein lipase, is the major
cholesterol-transporting lipoprotein in humans, carrying about two-thirds of the total
plasma cholesterol. The lipid composition of LDL is ~35% cholesteryl ester, ~12%
cholesterol, ~8% triglycerides, and 20% phospholipids. ApoB100, the solo apolipoprotein
crisscrossing LDL surface, contributes most if not all of the remaining 25%. The apoB100
on the surface of these particles is recognized by hepatic and extrahepatic LDLRs. This
interaction is responsible for ~75% of the clearance of LDL from the plasma, principally
through the liver (Havel and Kane 1989). Elevated plasma cholesterol concentrations,
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especial LDL concentrations, are strongly correlated with atherosclerotic coronary heart
disease (Watanabe and others 1985; Hobbs and others 1992).
Two isoforms of B apoproteins exist: apoB100 and apoB48 (Anant and Davidson,
2001). Both of them are derived from the same gene; however, apoB100 is produced in
liver, while apoB48 is the result of apoB mRNA editing that occurs only in the intestine. A
single cytosine is changed to a uracil, which changes the codon 2153 from a CAA
(glutamine) to the translational termination codon UAA. As a result, a shortened apoB
(apoB48), approximately 48% of the N-terminus of apoB100, is produced in the intestine.
Therefore, apoB48 is unique to chylomicrons and chylomicron remnants. These two B
proteins also differ in function (Brown and others 2000). ApoB100 is involved in
LDLR-meidated clearance of lipoprotein because it has a receptor-binding domain in its
C-terminal segment. Because apoB48 does not contain this portion of apoB, it does not
bind to LDLR well, if at all. Finally, apoB100 is required for the synthesis of VLDL by liver,
while apoB48 is required for the synthesis of chylomicron by small intestine.
LDLR is a transmembrane protein residing in the plasma membrane (Brown and
Goldstein 1986), responsible for clearing LDL and other lipoproteins from the plasma
through the binding to apoB100 or apoE. It is expressed by all cell types studied in
humans, mice, rabbits, dogs, etc. Due to the large mass, the liver is responsible for about
70% of the total body LDLR-mediated uptake of LDL, with the remaining one-third being
cleared by extrahepatic tissues (Pittman and others 1982). Lipoproteins bound to the
receptor are internalized via clathrin-coated pits on the plasma membrane. The coated
pits ‘pinch off ’ to form coated vesicles, then fuse together, lose their clathrin protein coat,
and become endosomes. Proton pumps acidify the endosomes, causing lipoprotein
20

release from the receptor. The receptor is then recycled to the cell surface while the
lipoproteins are delivered to lysosomes, where enzymes degrade the apoproteins into
their constituent amino acids and hydrolyze the cholesteryl esters to unesterified
cholesterol. The released cholesterol is used for the synthesis of cell membranes, and in
certain specialized cells it is a precursor for sterol end products. For example, in the
adrenal gland, cholesterol is converted into steroid hormones; while in the liver, it is
converted into bile acids (Brown and Goldstein 1986).
By 1) adjusting the number of LDLRs on their surface, 2) regulating the synthesis of
hydroxymethyglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme
involved in cholesterol biosynthesis, 3) regulating the activity of acyl coenzyme
A-cholesterol acyltransferase (ACAT), an enzyme that re-esterifies cholesterol into
cholesteryl esters stored in the cytoplasm as lipid droplets, cells maintain the amount of
intracellular cholesterol sufficient to perform various functions, but not so high as to
overload the cell.
In addition to controlling intracellular cholesterol, LDLRs regulate plasma LDL levels
and determine, in part, how much VLDL is converted to LDL. The importance of
receptor-mediated LDL clearance is demonstrated by two genetic defects: familial
hypercholesterolemia, in which the LDLR is defective, and familial defective apoB100, in
which the ligand (apoB100) is defective.
In familial hypercholesterolemia, individuals who inherit one copy of the mutant LDLR
gene possess LDL levels about twice that of normal, and are more susceptible to heart
attacks than normal individuals. Those who inherit two defective LDLR alleles
(homozygotes) have circulating LDL levels six to eight times higher than normal and
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usually have heart attacks before the age of 20. Massive accumulation of LDL in the blood
leads to two and half times longer survival of the LDL particles than that in the normal
individuals because the LDL particles must be removed by a metabolic pathway that is
not as efficient as the LDLR pathway. In addition to the slower removal of LDL, about
twice as much LDL is produced in familial hypercholesterolemic homozygotes. Thus, the
build-up of LDL in the plasma is due to both a slower utilization and increased production
of LDL particles (Goldstein and Brown 1979).
In the second genetic disorder – familial defective apoB100, a single amino acid
substitution in the receptor-binding domain of apoB100 abolishes the ability of LDL to bind
to the LDLR (Weisgraber and others 1988; Soria and others 1989). Individuals
heterozygous for this disorder have one population of normal LDL and one that binds
poorly, if at all, to LDLR. The abnormal LDL accumulates in the plasma to levels 50-70%
above normal. In contrast to familial hypercholesterolemic homozygotes, however, there
is no overproduction of LDL, and consequently, the LDL concentrations are not as
elevated. These two genetic disorders of the LDLR system clearly demonstrate the
physiological significance of the LDLR pathway in regulating plasma LDL levels.

Atherosclerosis

Atherosclerosis, the primary cause of heart disease and stroke, is responsible for
around 50% of all deaths in western societies (Lusis 2000). It is a progressive disease
characterized by the accumulation of lipids and fibrous elements in the artery wall.
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A variety of risk factors are associated with atherosclerosis. Genetic risk factors
include hypertension, diabetes, hyperlipidemia, and obesity etc. Environmental factors
such as high-fat diet, smoking, and lack of excercises, etc. are frequently observed in the
populations with atherosclerosis. Certain viral infections and bacterial infections have
also been implicated in atherosclerosis, such as human cytomegalovirus (CMV) (Speir
and others 1994; Zhou and others 1996) and Chlamydia pneumoniae (Campbell and
others 1998; Grayston 2000; Saikku 2000). Chlamydia pneumoniae is an obligate
intracellular bacterium which frequently causes airway infections in humans and has been
implicated in chronic inflammatory diseases in addition to atherosclerosis. CMV is a
member of the herpes virus group. Infection of CMV results in a variety of disorders which
depend largely on the immune status of the host.
Generally, atherosclerosis is characterized by three different stages: fatty streaks,
fibrous plaques, and advanced lesions. The early lesion of atherosclerosis, fatty streak,
consists of subendothelial accumulation of cholesterol-rich macrophages, also called
‘foam cells’. Though it is not clinically significant, fatty streaks are the precursors of more
advanced lesions – fibrous lesions. Typical fibrous lesions have a lipid-rich ‘necrotic core’
covered by a fibrous cap consisting smooth muscle cells (SMCs) and the extracellular
matrix generated by SMCs. In the most advanced stage, plaques become more complex,
with calcification in the necrotic core, ulceration at the luminal surface, and haemorrhage
from small vessels that grow into the lesion from the media of the blood vessel wall.
Plaque rupture occurs when the mechanical stresses in the fibrous cap exceed a critical
level that the cap tissue can withstand, leading to the formation of thrombus, one of the
life-threatening consequences of atherosclerosis.
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Pathogenesis of Atherosclerosis
A normal large artery consists of three morphologically distinct layers (Fig 3A). Intima,
the innermost layer, is bounded by a monolayer of endothelial cells on the luminal side
and a sheet of elastic fibres, the internal elastic lamina, on the peripheral side. The normal
intima consists of extracellular connective tissue matrix, primarily proteoglycans and
collagen. The media, middle layer, consists of SMCs. The adventitia, the outer layer,
consists of connective tissues with interspersed fibroblasts and SMCs.
Atherosclerotic lesions tend to occur at the sites where the direction of blood flow
changes. The primary event is the accumulation of LDL particles and their aggregates in
the subendothelial matrix. Trapped LDL undergoes modifications such as oxidation,
aggregation, lipolysis, and proteolysis. Modified LDL can stimulate the endothelial cells to
produce a number of pro-inflammatory molecules, including adhesion molecules and
growth factors such as macrophage colony-stimulating factor (MCSF), which mediates
the recruitment of monocytes and lymphocytes to the artery wall. Mice deficient in both
MCSF and apolipoprotein E have dereased atherosclerosis, which proves the critical role
of MCSF and macrophage recruitment in the development of atherosclerosis (Smith and
others 1995). After they migrate across the single layer of endothelial cells, monocytes
proliferate and differentiate into macrophages that can continuously uptake modified LDL
by scavenger receptors, which are not regulated by the intracellular content of
cholesterol, forming lipid-rich foam cells (Gerrity 1981) (Fig 3B).
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Figure 3 Pathogenesis of atherosclerosis. A: normal healthy artery wall; B: fatty streak
consisting lipid-rich foam cells; C: fibrous plaque consisting a necrotic core covered by a
fibrous cap; D: ruptured plaque with formation of thrombus in the artery.

Cytokines and growth factors secreted by macrophages and T cells can lead SMCs to
migrate and accumulate in the intima (Schonbeck and others 2000). The SMC-derived
extracellular matrix, together with SMC, forms the fibrous cap. Underneath is the
so-called lipid core, consisting of a growing mass of extracellular lipids due to the death of
foam cells. The shoulder region of the plaque is generally rich in foam cells (Fig 3C).
The development of thrombus-mediated acute coronary events depends primarily on
the composition and vulnerability of a plaque. Vulnerable plaques generally have very thin
fibrous caps and increased numbers of inflammatory cells. Once the fibrous cap ruptures,
exposure of the extracellular contents of the necrotic core such as tissue factor, a key
protein in the initiation of the coagulation cascade, to the blood leads to the formation of
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thrombus or blood clot (Fig 3D), resulting in myocardial infarction or stroke – the most
important clinical complication. Rupture frequently occurs at the lesion edges, which are
rich in foam cells, suggesting a significant role of foam cells in thrombosis (Lusis 2000).

Apoptosis in Atherosclerosis
Macrophages are involved in all stages of atherosclerosis. The expression of a variety
of genes and their proteins which affect lipoprotein metabolism and cholesterol
accumulation in macrophages has been shown to influence the progression of
atherosclerosis (Linton and Fazio 2001; Linton and Fazio 2003). In addition, upon
activation, macrophages generate a large number of cytokines and growth factors that
regulate lesion development in both paracrine and autocrine manners (Frostegard and
others 1999; Seshiah and others 2002; Linton and Fazio 2003).
Macrophages in atherosclerotic lesions have been shown to have cellular
characteristics of both necrosis and apoptosis (Hegyi and others 1996). The
pathophysiological consequences of these two different types of cell death are still under
investigation. All three of the major cell types found in atherosclerotic lesions (e.g.
macrophages, SMCs, and endothelial cells) can undergo apoptosis. Given the complexity
of atherosclerotic plaque, apoptosis in these different cell types may play different roles in
atherogenesis (Kockx and Herman 2000; Lusis 2000).
The majority of apoptotic cells in atherosclerotic lesions are macrophages localized
near the necrotic areas of advanced lesions (Ball and others 1995). Overexpression of
Bax and other related apoptotic proteins has been found in all stages of human
atherosclerotic plaques (Kockx and others 1998; Martinet and others 2002; Saxena and
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others 2002). In vitro, Bax activation has been shown to occur during apoptosis resulting
from free cholesterol loading of macrophages (Yao and Tabas 2001) or after treatment of
macrophages with oxysterols which are cytotoxic components of oxidized LDL (Panini
and Sinensky 2001).
Although foam cell apoptosis has long been hypothesized to contribute to the
development of the lipid core (Ball and others 1995; Hegyi and others 1996), the role of
macrophage apoptosis in atherosclerosis remains unclear. Macrophage death may
reduce the production of growth factors and inflammatory cytokines, which in turn may
impede the development of atherosclerosis. On the other hand, loss of macrophages may
promote pro-atherogenic factors such as decreased production of apoE and reduced
scavenging of toxic substances (i.e. oxidized LDL (oxLDL)) (Linton and others 1995;
Nicholson and others 2001; Platt and others 2002).

Mechanisms of Apoptosis Induction during Atherosclerosis
Possible causes of cell death in atherosclerotic lesions include exposure to oxidized
lipoproteins, cholesterol-induced cytotoxicity (Warner and others 1995; Tabas and others
1996), growth factor deprivation (Chin and others 1999), and exposure to other arterial
wall factors such as inflammatory cytokines and nitric oxide (Mitchinson and others 1996;
Lopez-Collazo and others 1998).

OxLDL/oxyserol-induced Apoptosis OxLDL can be generated in vivo by at least
three classes of mechanisms: 1) autoxidation in the presence of transition metals (Morel
and others 1983; Lamb and others 1995); 2) cell-mediated oxidation (Morel and others
1984; Steinbrecher and others 1984); and 3) plasma enzyme-mediated oxidation
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(Parthasarathy and others 1985; Daugherty and others 1994; Yla-Herttuala and others
1995).
It has been proposed that oxidative modifications of LDL increase its atherogenicity
and that the resulting oxLDL, but not the native LDL, plays a pivotal role in the
development of atherosclerotic lesions. OxLDL is involved in many events that are
associated with atherosclerosis: it induces the expression of adhesion molecules on
endothelial cells (Kume and others 1992) which will recruit monocytes or lymphocytes
from the blood, the transformation of macrophages and smooth muscle cells to foam cells
(Henriksen and others 1981), the production of various proinflammatory cytokines and
growth factors by almost all vascular cells (Kume and Gimbrone 1994; Nakano and others
1994), the proliferation and migration of vascular SMCs (Quinn and others 1988; Yui and
others 1993; Auge and others 1996;), the retardation of endothelial regeneration
(Murugesan and Fox 1996), and it increases the procoagulant activity on the vascular
cells (Aupeix and others 1996). These changes are suggested to eventually result in the
formation of atheromatous lesions.
OxLDL also exhibits a dramatic cytotoxic effect on several vascular cell types,
including SMCs, macrophages, and endothelial vascular cells. It has been well
established that vascular cells - particularly macrophages (Reid and others 1993;
Hardwick and others 1996), and endothelial cells (Escargueil-Blanc and others 1997) undergo apoptosis after uptake of circulating oxLDL (Mitchinson and others 1996).
OxLDL induces both the morphological changes and DNA fragmentation characteristic of
apoptosis in cultured smooth muscle cells, macrophages, endothelial cells, and lymphoid
cells (Dimmeler and others 1997; Escargueil-Blanc and others 1998; Brown and Jessup
1999). The cytotoxic effect of oxLDL depends on concentration and oxidative
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modification. High concentrations of oxLDL are pro-apoptotic, whereas low
concentrations are mitogenic for vascular SMCs. Regarding the degree of oxidation,
Siow and others (1999) provided evidence that moderately oxLDL, with its high lipid
hydroperoxide content, seems to be more cytotoxic than mildly or highly oxLDL (Siow and
others 1999; Napoli and others 2000). In contrast, protein modifications do not seem to be
necessary for LDL-induced cytotoxicity.
The oxidation of LDL by incubation with cells results in marked changes that include
an increased lysolecithin content; a decreased content of polyunsaturated fatty acids
associated with an abundance of products of the peroxidation of these acids; a
fragmentation of apolipoprotein B100, an increased density, and an significant increase in
the oxysterol levels (Steinbrecher and others 1984). Oxysterols have been demonstrated
to exist both in oxLDL (Colles and others 1996) and in atherosclerotic plaque (Carpenter
and others 1993). Various oxysterols in oxLDL have been shown to induce apoptosis in
endothelial cells (Harada-Shiba and others 1998), monocytic cell lines (Aupeix and others
1995), thymocytes (Christ and others 1993), and smooth muscle cells (Ares and others
1997). Therefore, the cytotoxicity of oxLDL can best be accounted for by the formation of
these oxysterols.
Oxysterols are 27-carbon products of cholesterol oxidation (Brown and Jessup 1999).
Various oxysterols have been detected in appreciable quantities in human tissue and
fluids, including human plasma, atherogenic lipoproteins, and atherosclerotic plaque.
How these oxysterols originate in vivo is not fully known. Some researchers claim that
they arise principally from dietary sources while others contend that they are generated
by non-enzymatic oxidation in vivo (Brown and Jessup 1999).
Of the various oxysterols, 7-ketocholesterol has been reported to be the predominant
sterol in oxLDL (Zhang and others 1990; Jialal and others 1991; Brown and others 1996;
Chang and others 1997). To lesser contents, 7α-OH-cholesterol and 7β-OH cholesterol
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are also major oxysterols detected in oxLDL. 25-hydroxycholesterol (25-OHC) was
detected at a very low level in oxLDL, however it is the most extensively studied due to its
ability to inhibit HMG-CoA reductase activity (Smith and Johnson 1989), reduce
transcription of LDL receptor (Sudhof and others 1987), stimulate cellular cholesterol
esterification by the activation of ACAT (Brown and others 1975; Zhang and others 1990),
and induce apoptosis in a variety of different cell types (Smith and Johnson 1989).
25-OHC down regulates HMG-CoA reductase and the LDL receptor by blocking the
proteolytic activation of two sterol-regulated transcriptional factors, sterol response
element binding protein-1 (SREBP-1) and SREBP-2 (Yang and others 1995b). It has
been found in human atheromatous plaques and aortic tissues (Hodis and others 1991)
and proposed to disrupt endothelial cell barrier function, disorganize cytoskeletal protein,
and inhibit gap junctional communication. As a model compound, 25-OHC has been used
to induce apoptosis in monocyte, macrophage, and lymphoid cell lines in the range of
1-10 µM. 7-ketocholesterol has also been shown to induce apoptosis in vascular
endothelial and smooth muscle cells (Nishio and Watanabe 1996; Lizard and others
1998), as well as macrophages (Liao and others 2000; Geng and others 2003).
The relative toxicities of oxysterols to cells in vitro depend very much on the conditions
under which exposure is conducted, the cell type, and even the species. For example,
the concentration of oxysterol required to achieve detectable toxicity is higher in the
presence of serum or lipoproteins than in serum-free media; this is probably due to the
capacity of lipoproteins to absorb oxysterols and reduce their effective concentration as
well as direct antagonism of oxysterol toxicity by cholesterol (Clare and others 1995;
Colles and others 1996; Nishio and Watanabe 1996).
Oxysterols induce apoptosis in many cell types including vascular cells such as
endothelial cells (Ramasamy and others 1992), macrophages, SMC, and lymphocytes.
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Evidence includes oxysterol-stimulated DNA fragmentation (Christ and others 1993;
Aupeix and others 1995; Clare and others 1995; Ares and others 1997), decreased
expression of Bcl-2 (Nishio and Watanabe 1996), activation of Bax (Rusinol and others
2004), activation of the protease caspase 3 (a key mediator of apoptotic cell death) (Ares
and others 1997). Caspase 3 inhibition partially blocked apoptosis induced by oxysterol
(Nishio and Watanabe 1996).
Oxysterol induced apoptosis proceeds partially through the mitochondrial death
pathway (Panini and Sinensky 2001). It has been demonstrated lately (Rusinol and others
2004) that oxysterols induce the degradation of the prosurvival protein kinase Akt (protein
kinase B), which leads to the activation of proapoptotic proteins Bim and Bad and
down-regulation of the antiapoptotic Bcl-xL. These responses would be expected to
activate the proapoptotic protein Bax and Bak, leading to the release of cytochrome c.

Free Cholesterol-induced Apoptosis As stated above, the toxicity of
oxLDL/oxysterols is partially accounted for the induction of apoptosis in atherosclerotic
lesions. In addition, free cholesterol accumulation in foam cells has also been reported to
be cytotoxic (Ross 1995; Yao and Tabas 2000; Yao and Tabas 2001). Macrophages in
atherosclerotic lesions have been shown to accumulate large amounts of free cholesterol
(Shio and others 1979; Rapp and others 1983; Small and others 1984; Lundberg 1985).
Free cholesterol loading of cultured macrophages is a potent inducer of cell death
(Warner and others 1995; Tabas and others 1996) probably through the inhibition of
certain critical plasma membrane enzymes (Papahadjopoulos 1974; Yeagle 1991;
Kellner-Weibel and others 1998). In fact, Papahadjopoulos demonstrated 30 years ago
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that free cholesterol-mediated inhibition of two critical plasma membrane enzymes, (Na+
K+)-ATPase and adenylate cyclase, led to cellular death and proposed that these events
may play an important role in the development of atherosclerosis.
Most recently, free cholesterol loading in cultured mouse peritoneal macrophages has
been reported to induce apoptosis by activating both the death receptor pathway (Yao
and Tabas 2000) and the mitochondrial pathway (Yao and Tabas 2001). Increased level
of Bax protein in both cellular and mitochondrial fractions has been observed as early as
4 h after free cholesterol loading in cells (Yao and Tabas 2001).
In addition, ER has also been reported to be the site of free cholesterol-induced
cytotoxicity in macrophages (Feng and others 2003). Free cholesterol loading leads to the
depletion of ER Ca2+ storage, an event known to induce the unfolded protein response
(UPR). Activation of UPR results in the expression of the cell death effector CHOP, a
transcription factor activated during the cell responses to injury associated with ER stress
(Zinszner and others 1998; Oyadomari and others 2002). In the presence of selective
inhibitor of cholesterol trafficking to the ER, the UPR, caspse-3 activation, and apoptosis
are markedly inhibited. Consistently, Chop-/- macrophages are protected from
cholesterol-induced apoptosis.

Mouse Models of Atherosclerosis
Mice are highly resistant to atherosclerosis. On a low cholesterol, low fat diet, they
typically have cholesterol levels of <100 mg/dl, mostly contained in the antiatherogenic
HDL fraction, and they do not develop lesions. However, when they are fed a very high
cholesterol, high fat diet, their plasma cholesterol levels rise by a factor of two to three,
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with the majority now in the non-HDL fraction (Breslow 1996). After months on this diet,
certain inbred strains, such as C57BL6, develop several layers of foam cells in the
subendothelial space near the aortic valve leaflets. Although promising, this model has
two problems. First, lesions often occur at the branch points of major vessels and
progress to the fibrous plaque stage in humans, but only occur in the region of aortic valve
leaflets in C57BL6 mice and do not progress past the fatty streak stage. Second, the diet
required to induce atherosclerosis is unphysiological, as it contains 10 to 20 times the
cholesterol of a Western-type diet.
The apolipoprotein E deficient mouse (ApoE-/-) was the first model generated with
these two problems resolved (Plump and others 1992; Zhang and others 1992). ApoE,
which is made primarily in the liver, is a surface constituent of almost all lipoprotein
particles other than LDL, and it is a ligand for lipoprotein recognition and clearance by
lipoprotein receptors LDLR and chylomicron remnant receptor. In apoE-/- mice,
accumulations of chylomicron and very low density lipoprotein (VLDL) remnants are the
major stimuli for atherosclerosis. These mice develop not only fatty streaks but also
widespread fibrous plaque lesions spontaneously at vascular sites typically affected in
human atherosclerosis (aortic valve leaflet regions and branch points of major vessels).
The apoEs produced by bone marrow derived macrophages are sufficient to inhibit the
development of atherosclerosis in apoE-/- mice (Linton and others 1995).
The LDLR deficient mouse (LDLR-/-) is another frequently used model in
atherosclerosis studies (Ishibashi and others 1994). As described before, LDLR is
expressed by all cell types so far studied. The liver is responsible for about 70% of the
total body LDLR-mediated uptake of lipoproteins. Cell surface LDL receptors recognize
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apolipoprotein B on LDL and apoE on IDL and remove these lipoproteins from the
circulation. LDLR activity is also expressed by human monocyte-derived macrophages
(Traber and Kayden 1980) and arterial macrophage-derived foam cells (Jaakkola and
others 1989). However, LDLR expressed by macrophages has no significant effect on the
development of atherosclerosis (Boisvert and others 1997; Fazio and others 1997b;
Herijgers and others1997). LDLR-/- mice have increased plasma cholesterol, with most of
the increase in the IDL and LDL lipoprotein fractions. However, unlike apoE-/- mice,
LDLR-/- mice do not develop atherosclerosis on low-cholesterol, low-fat diet. While fed a
Western diet (0.15% cholesterol and 21% fat), they produce massive fatty streak lesions
with lipid-rich necrotic core covered with foam cells and/or fibrous caps which mainly
localize in the aortic valve leaflet regions.
There are two versions of apolipoprotein B as described above, apo B100 and apo
B48. In human, apoB100 is produced by liver and secreted in VLDL, while apoB48 is
generated by small intestine and secreted in chylomicron. The apoB100-containing
VLDLs give rise to apoB100-containing IDLs, which are cleared from plasma almost
entirely by LDLR (Brown and Goldstein 1983; Havel 1987). The apoB48-containing
chylomicrons are hydrolysed into chylomicron remnant and cleared by chylomicron
remnant receptor (Scott 1989; Chan 1992; Higuchi and others 1992). In LDLR deficiency,
the apoB100-containg IDLs remain in the the plasma where they are converted into LDL.
Mouse livers, unlike those of humans, produce both apo B100 and apo B48, which are
incorporated into VLDL (Scott 1989; Chan 1992; Higuchi and others 1992). The
apoB48-containing VLDLs, like intestinal chylomicrons, generates apoB48-containing
IDLs that can bind to chylomicron remnant receptors, and rapidly cleared even in the
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absence of LDLR (Kita and others 1982; Rubinsztein and others 1990). Thus, the LDLR-/mice do not give rise to appreciable amounts of plasma LDL as happens in human
homozygous for LDLR gene described above.

Bone Marrow Transplantation (BMT)
The possibility of BMT came first from studies in the mouse. At the end of World War II
following the atomic bomb explosions, there was a great deal of interest in how radiation
damages living organisms. It became recognized that the marrow is the organ most
sensitive to radiation and that death following low-lethal exposures was due to marrow
failure.
Early transplantation studies documented the ability of bone marrow cells to
repopulate lethally irradiated animals (Lorenz and others 1951). Subsequent studies have
shown that approximately 105 nucleated marrow cells are necessary to reestablish
hematopoiesis in murine-irradiated hosts (Boggs and others 1982; Harrison and Astle
1982). Marrow grafts are traditionally established by infusing unmanipulated suspensions
of aspirable, donor-derived marrow cells into the respective recipient. The marrow
suspension consists of a complex mixture of cells that includes the essential population of
repopulating cells as well as cells that are part of the regulatory network of hematopoiesis,
such as T lymphocytes. Marrow given intravenously was just as effective in repopulating
the marrow spaces as marrow given by any other route (Van Bekkum and others 1956).
The marrow cellularity in recipient increases rapidly over the following 2 to 4 weeks after
BMT, and shows morphological evidence of all myeloid components (van den Berg and
others 1990).
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Conditioning programs serve to suppress the recipient’s immune system for
acceptance of the marrow graft and to eradicate the recipient’s underlying disease that
made treatment by BMT necessary. Total body irradiation has been the most commonly
used conditioning program for BMT. Mice not given a marrow infusion usually die from
complications of marrow failure within 2 weeks after a lethal dosage of irradiation.
Consistent survival following lethal doses of total body irradiation can be obtained by
giving an infusion of marrow, fresh or cryopresserved (Mannick and others 1960; Cavins
and others 1962).
Complete engraftment can be sustained by a limited number of hematopoietic clones.
Introduction of genetic markers into individual hematopoietic stem cells provided a
method of tracing their progeny (Lemischka and others 1986). A period of instability in the
clonal composition of the graft was observed early after BMT. However, the clonal
composition of the graft stabilized after some weeks and remained constant for the life
span of the animals. In addition, the marrow of engrafted animals appears to contain
repopulating cells at a number that is sufficient to reestablish hematopoiesis in a second
generation of recipients. These observations suggest that murine hematopoietic clones
can be expanded to function for at least two successive generations of BMT recipients
(Jordan and Lemischka 1990).
In bone marrow derived cells, macrophages affect the development of atherosclerosis
most. Recently, BMT has been broadly used to study the physiological or pathological
functions of macrophages and macrophage gene expression in atherogenesis (Linton
and others 1995; Herijgers and others 1997). By repopulating the recipient mice with the
donor marrow either deficient in or overexpressing a gene of interest, the significant
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functions of many proteins produced by macrophages have been defined. For example,
apoE produced by bone marrow derived macrophages has been found to be sufficient to
inhibit atherosclerosis in apoE-/- mice (Linton and others 1995). The in vivo effects on
atherogenesis of many other key genes have also been defined through BMT, such as
ACAT1 (Fazio and others 2001), lipoprotein lipase (Babaev and others 1999), NF-κB
(Kanters and others 2003), etc.
As described above, LDLRs expressed by bone marrow derived macrophages have
no significant effect on the development of atherosclerosis in LDLR-/- mice (Boisvert and
others 1997; Fazio and others 1997b; Herijgers and others 1997); however, apoEs
produced by bone marrow derived macrophages are sufficient to inhibit the development
of atherosclerosis in apoE-/- mice (Linton and others 1995). Thus, in the studies of
atherosclerosis, LDLR-/- mice are more often chosen as the model than apoE-/- mice
because LDLR-/- mice can be directly reconstituted by bone marrow isolated from donor
mice of interest. In certain cases that apoE-/- mice are appreciated, most often apoE-/mice have to be interbred with the mice of interest, generating springs that carrying the
genotypes of both parents, which is time-consuming and highly unefficient.

Specific Aims

The goal of the present studies is to determine the consequences of macrophage
apoptosis in atherogenesis. Because of the well established and accepted role of Bax in
apoptosis, as well as the specific observations implicating Bax activation in macrophage
apoptosis associated with atherogenesis, we chose to examine whether Bax deficiency
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will produce resistance, at least partially, to oxysterol-induced macrophage apoptosis in
vitro by inhibiting Bax expression in cultured macrophage cell line P388D1 using siRNA.
We also sought to determine if primary macrophages isolated from Bax-/- mice were
resistant to the induction of apoptosis by oxysterols. The in vivo effect of Bax deficiency in
macrophages on the development of atherosclerosis was investigated by transplanting
atherosclerosis susceptible mice with Bax positive (WT) or deficient (Bax-/-) bone
marrow. Because the donor mice are positive for both apoE and LDLR, LDLR-/- mice
were chosen as the model for the current study due to the reasons described above.
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CHAPTER 2
MATERIALS AND METHODS

Materials
Cell culture media and supplements were obtained from BioWhitaker (Walkersville,
MD). Fetal bovine serum (FBS) was from Hyclone (Logan, UT). Oligonucleotides were
purchased from Integrated DNA Technologies, Inc. (Coralville, IA). Oxysterols were from
Steraloids (Newport, RI). All the other reagents were obtained from Fisher Scientific and
were of the highest quality available.

Mice
Both male LDLR-/- recipient mice (B6.129S7-Ldlrtm1Her) and Bax-/- donor mice
(B6.129X1-Baxtm1Sjk) are from The Jackson Laboratory (Bar Harbor, ME) and on C57BL6
background. All mice were maintained in microisolator cages on autoclaved rodent chow
containing 4.5% fat (Purina Mills Inc., St. Louis, MO) and autoclaved acidified water (pH
2.8). Experimental protocols were performed according to the regulations of Vanderbilt
University’s Animal Care Committee and East Tennessee State University Animal Care
Committee.

SiRNA Construct for Bax
To suppress the expression of Bax, a plasmid that generates siRNAs targeting Bax
mRNA for degradation, SiBax, was constructed using pSilencer1.0 U6 vector (Ambion
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Inc., Austin, TX) (Fig 4). Two complementary oligonucleotides were annealed and cloned
into the ApaI/EcoRI-digested pSilencer: Bax-Forward, ACTGGTGCTCAAGGCCCTGTT
CAAGAGACAGGGCCTTGAGCACCAGTTTTTTT; and Bax-Reverse, AATTAAAAAAAC
TGGTGCTCAAGGCCCTGTCTCTTGAACAGGGCCTTGAGCACCAGTGGCC. To make
the negative control vector R-Bax, two complementary oligonucleotides with a
randomized Bax target sequence were annealed and cloned into the
ApaI/EcoRI-digested pSilencer: R-Bax-Forward, ACCGCTCGAGCGTGCTAGTTTCAAG
AGAACTAGCACGCTCGAGCGGTTTTTTT; and R-Bax-Reverse, AATTAAAAAAACCG
CTCGACGGTGCTAGTTCTCTTGAAACTAGCACGCTCGAGCGGTGGCC. The ligation
reactions were performed using a Fast-Link DNA ligation kit (Epicentre, Madison, WI)
according to manufacturer’s instructions. A portion of the ligation products was used to
transform competent JM109 cells (Promega, Madison, WI). The recombinant cells were
selected on LB plates containing 50 µg/ml ampicillin. Selected colonies were grown in
100 ml LB medium containing 50 µg/ml ampicillin. Plasmids were purified using a QIAfilter
plasmid midi kit (Qiagen, Valencia, CA) as directed. The plasmids were then sequenced
(Molecular Biology Core Facility at ETSU) using T3 primer to verify the proper
construction.
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Figure 4 pSilencer 1.0-U6 Vector. A representative insert is shown with stem region in the
hairpin structure shaded. (http://www.ambion.com/techlib/misc/vectors/1.0_U6.html)

Stable Suppression of Bax gene in P388D1 Cells
All cell cultures were maintained in a humidified atmosphere of 5% CO2 and 95% air at
37 °C. P388D1 cells, a mouse lymphoblast cell line with macrophage-like morphololgy,
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
FBS, 2 mM glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml
streptomycin.
Stable suppression of Bax gene was achieved by cotransfecting P388D1 cells (2 x
106) with a plasmid vector carrying the neomycin-resistant gene, pEGFP (Clontech, Palo
Alto, CA), and either SiBax or R-Bax using LipofectAMINE Plus (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. Stable clones were first selected by
culturing single cell/well with 100 µl medium containing 1 mg/ml G418 in 96-well
microculture plate for 7 days, followed by 14 days in 0.25 mg/ml G418. The integration of
the pSilencer vector into host genomes of the G418 resistant clones was then screened
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by polymerase chain reaction (PCR) on a PCR Express thermocycler (Hybaid) using
primers complementary to the vector sequences: pSi-Forward, CTCCCCGTCGTGTAGA
TAACTACG; pSi-Reverse, GTCGCCGCATACACTATTCTCAG.
The PCR reaction solution contained ~100 cells per reaction, 200 µM dNTP mix, 0.2
µM of each primer, 1.25 units of ExTaq DNA polymerase in 1x ExTaq DNA polymerase
buffer (Takara Bio, Inc., Shiga, Japan). After 30 PCR cycles ( 94 °C for 1 min, 57°C for 45
sec, 72°C for 1 min), the 500-bp PCR product was separated by gel electrophoresis on
1.0% agarose gel, and then extracted using gel extraction kit (Qiagen, Valencia, CA). To
further confirm the PCR product was derived from the integrated vector sequence, the
PCR product was subjected to restriction analysis using restriction enzyme PvuI, whose
restriction site was included in the original pSilencer vector. The digestion process was
expected to generate two fragments, 374 bp and 126 bp.
PCR positive and G418-resistant SiBax clones were then subjected to selection in
medium containing 10 µg/ml 25-OHC for 68 h. The surviving SiBax cells were expanded
and maintained in medium containing 0.5 mg/ml G418.

Immunoblotting to Examine Bax Suppresion in P388D1 cells
The suppression of Bax expression was determined by immunoblotting whole cell
lysates prepared from the isolated SiBax clones and G418-resistant R-Bax clones.
P388D1 cells were collected by centrifugation at 100 x g for 5 min. After rinsing with cold
phosphate buffered saline (PBS), the cells were treated with lysis buffer containing 20
mM Tris (pH7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerol phosphate, 1 mM Na3VO4, and 1 µg/ml
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leupeptin. Unbroken cells and membrane debris were removed by centrifugation at
10,000 x g for 10 min, and the protein concentration of the supernatant was determined
by micro-BCA assay (Pierce, Rockford, IL). Proteins were resolved by SDS-PAGE on
4-12% NuPage gels (Invitrogen) and transferred to polyvinylidene difluoride (PVDF)
membranes (Immobilon-P, Millipore Corp.). The blots were blocked in 3% non-fat milk in
PBS and then probed using antibodies specific for Bax (Cell Signaling Tech., Inc.,
Beverly, MA) at 1:1000 dilution, Bak (Cell Signaling Tech., Inc.) at 1:2000 dilution, Akt
(Santa Cruz Biotehnology, Santa Cruz, CA) at 1:2000 dilution, and horseradish
peroxidase (HRP)-conjugated secondary antibodies at 1:5000 dilution. The protein bands
were visualized by enhanced chemiluminescence using SuperSignal® West Pico
chemiluminescent substrate (Pierce) as directed.

Caspase 3 Activity Assay in P388D1 cells
P388D1 cells were seeded at 2 x 106/well in 12-well culture plates and cultured in
DMEM medium supplemented with 5% FBS plus 10 µg/ml 25-OHC or an equivalent
volume of ethanol alone (control). Following a 16-h incubation, cells were collected by
centrifugation at 1000 x g for 5 min, washed with PBS, resuspended in lysis buffer (10 mM
Tris, pH7.5, 130 mM NaCl, 1% Triton X-100, 10 mM sodium Pi, and 10 mM sodium PPi).
After 10 min incubation on ice, unlysed cells and membrane fraction were removed by
centrifugation at 12,000 x g for 20 min at 4 °C. The sample protein concentration was
determined using micro-BCA kit (Pierce). Caspase 3 activity was assayed by incubating
equivalent protein amounts of each sample in caspase assay buffer (20 mM Hepes,
pH7.5, 10% glycerol, and 2 mM dithiothreitol) containing 5 µM caspase 3 substrate
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(Ac-DEVD-7-amino-4-trifluoromethyl coumarin, BioMol, Plymouth Meeting, PA) at 37 °C
for 2.5 h in the presence or absence of 100 µM caspase 3 inhibitor DEVD-CHO (BioMol).
Liberated 7-amino-4-trifluoromethyl coumarin was measured using a spectrofluorometer
(FluroMax 3 equipped with a microplate reader, Jobin-Yvon Inc.) with an excitation
wavelength of 400 nm and an emission wavelength of 505 nm. For each sample, the net
caspase-3 activity was determined by subtracting the relative fluorescent light units
(RFUs) obtained in the absence of DEVD-CHO from the relative RFUs obtained in the
presence of DEVD-CHO, and normalized to the protein content of the sample. The results
were presented as the mean±S.D. of triplicate samples.

Peritoneal Macrophage Isolation and Caspase 3 Activity Assay
Mouse peritoneal macrophages were isolated 3 days after intraperitoneal injection
with 1.5 ml of 6% thioglycollate. Cells were seeded in DMEM at 1 x 106/well in 12-well
culture plates. The nonadherent cells were washed away with PBS 2 hrs after seeding,
and the culture medium was changed to DMEM+5% FBS. After the overnight incubation,
cells were treated with 10 µg/ml 7-KC dissolved in ethanol in the culture medium for 12
hrs. Each treatment was performed in triplicate. Control groups were treated with an
equal volume of ethanol. The caspase 3 activity was assayed using CPP32/Caspase-3
fluorometric protease assay kit from Chemicon International Inc. (Temecula, CA)
according to the manufacturer’s directions. For each sample, 100 µl of cell lysate was
incubated with 100 µl reaction buffer plus 1 µl of caspase 3 substrate
(Ac-DEVD-7-amino-4-trifluoromethyl coumarin) in a 96-well plate at 37 °C for 1.5 hrs. The
relative fluorescent unit (RFU) of each sample generated by 7-amino-4-trifluoromethyl
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coumarin was read by Fusion spectrofluorometer (Perkin-Elmer, Boston, MA) at an
excitation wavelength wavelength of 400 nm and an emission wavelength of 485 nm. A
mixture of 100 µl cell lysis buffer and 100 µl reaction buffer plus 1 µl substrate was used
for a blank reading, which was subtracted from all the experimental readings. For each
sample, the final RFU was then normalized to the protein concentration of the sample
determined using micro-BCA kit (Pierce). The data were presented as the mean±S.D. of
triplicate treatments.

Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick End Labeling (TUNEL)
Mouse peritoneal macrophages were cultured at 500,000 cells/chamber in DMEM
supplemented with 5% FBS in 4-chamber Lab-Tek chamber slides (Nalge Nunc
International, Naperville, IL). Following the incubation with either 10 µg/ml 25-OHC or 0.5
µg/ml staurosporine (a protein kinase inhibitor), cells were fixed in 4% paraformaldehyde
in PBS and permeabilized in 0.1% Triton X-100, 0.1% sodium citrate on ice for 5 min.
After incubation with a 50 µl mixture of deoxynucleotidyl transferase and nucleotide
containing fluorescein-labeled dUTP (ApoAlert DNA fragmentation assay kit, Clontech,
Palo Alto, CA) at 37 °C for 1 h in a humidified chamber, cells were washed with PBS twice
and counterstained with propidium iodide (PI). TUNEL positive cells and PI staining
positive cells were counted in 10 viewfields (400x) under fluorescent microscope with
GFP and rodamine filters. The data were expressed as the mean percentage of TUNEL
positive cell number per field / PI staining positive cell number per field ± S.D.
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Bone Marrow Transplantation
To study the in vivo effect of Bax deficiency in macrophages on the development of
atherosclerosis, LDLR-/- mice were reconstituted with bone marrow isolated from either
WT or Bax-/- donor mice. One week before and 2 weeks after transplantation, all recipient
LDLR-/- mice were given acidified water containing 5 mg/L neomycin and 25000 units/L
polymyxin B sulfate (Monarch Pharmaceuticals, Bristol, TN). Eight-week-old male
LDLR-/- mice received 10 Gy whole body irradiation from a cesium gamma source and
were transplanted with 5x106 bone marrow cells from WT C57BL6 or Bax-/- donor mice
as described (Linton and others 1995). Briefly, the bone marrows from femurs and tibias
of donor mice were flushed with RPMI 1640 medium (Gibco, Invitrogen) supplemented
with 2% FBS (Hyclone, Logan, UT) and heparin 5 units/ml. Single cell suspension was
prepared by passing the bone marrow through a 27 gage needle several times. After
washing with fresh RPMI 1640 plus 2% FBS, bone marrow cells were resuspended in
RPMI 1640 without FBS. Five million bone marrow cells in 0.2 ml RPMI media were
injected into the retro-orbital venous plexus of each recipient mouse. Three weeks later
they were fed a Western diet (21% fat and 0.15% cholesterol; Harlan Teklad, Madison,
WI) for 10 weeks.

Determination of Chimerism by Western blotting. Before sacrifice, peritoneal
macrophages were collected from 4 recipient mice randomly chosen from each group.
Whole cell lysate was prepared in buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, protease
inhibitor cocktail 1% (Sigma). Protein concentration was determined by modified Lowry
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assay using Dc protein assay reagent (Bio-Rad). Protein samples (20 µg each) were
separated on a NuPage 10% Bis-Tris Gel, and transferred onto Hybond-P PVDF
membrane (Amersham Biosciences). Bax protein was detected using rabbit polyclonal
anti-Bax (Upstate Biotech, Lake Placid, NY) at 1:1000 dilution and HRP-conjugated goat
anti-rabbit IgG (Upstate Biotech) at 1:5000 dilution. ECL reagents (Amersham
Biosciences) were used for the visualization. The same blot was stripped in a buffer
containing 2% SDS, 100 mM 2-mercaptoethanol, 62.5 mM Tris-HCl, pH 6.8, at 55 °C for
10 min and reprobed for beta-actin using rabbit polyclonal anti-beta actin (Abcam,
Cambridge, MA.) and HRP-conjugated goat anti-rabbit IgG both at 1:5000 dilution.

Determination of Chimerism by PCR. Genomic DNA extracted from whole blood 8
weeks after transplantation was subjected to PCR using primers for wild type or mutant
LDLR gene. We took advantage of the fact that the donor mice (wild type or Bax-/-) were
LDLR+/+, while the recipients in both groups were LDLR-/-. Eight weeks after bone
marrow transplantation, 6 or 7 mice from each group were randomly picked. After
overnight fasting, 100 µl of blood was drawn by retro-orbital venous plexus puncture
under anesthesia. The genomic DNA was extracted using PUREGENE DNA purification
system (Gentra Systems, Minneapolis, MN). The PCR reactions (94°C for 45 sec, 55 °C
for 45 sec, 72 °C for 1 min, 30 cycles) were carried out on a thermocycler (Applied
Biosystems, Foster City, CA) using LDLR+/+ specific downstream primer
5’-CGCAGTGCTCCTCATCTGACTTGTCTTGTTGT-3’, LDLR-/- specific downstream
primer 5’-AGGTGAGATGACAGGAGATC-3’. The common upstream primer was:
5’-ACCCCAAGACGTGCTCCCAGGATGA-3’. Each reaction contained 50 ng DNA
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template, 0.2 mM dNTP mixture, 1.5 mM MgCl2, 0.2 µM of each primer, 2.5 units of
recombinant DNA Taq polymerase, and 1x PCR buffer. All the PCR reagents were from
Invitrogen. DNA samples from WT C57BL6 and LDLR-/- mice were used as the controls.
A 400 bp PCR product was expected from the WT LDLR gene, while an 800 bp PCR
product was expected from the interrupted LDLR.

Serum Cholesterol, Triglyceride Assay, and Lipoprotein Analysis by FPLC
Blood samples were collected by retro-orbital venous plexus puncture under
anesthesia after overnight fasting. Serum was separated by centrifugation at 10,000 x g
for 10 min at 4 °C. Total cholesterol and triglycerides were determined using Cholesterol
Reagent and Triglycerides GPO reagent kits (Raichem, San Diego, CA). Serum samples
were diluted at 1:100 in diH2O. For each sample, 100 µl sample dilution was mixed with
100 µl Cholesterol Reagent or Triglycerides GPO reagent in 96-well plate. For standard
solutions, 6 different concentrations were provided: 0.5, 1.0, 1.5, 3.0, 6.0, and 10.0 mg/dl.
Following 10-min incubation at 37 °C, the sample absorbance was read using a
spectrophotometer at 500 nm for cholesterol and 520 nm for triglycerides. Each sample
was assayed in triplicate.
To analyze the serum lipoprotein profiles, several serum samples in each group were
randomly chosen and subjected to gel filtration chromatography as described (Fazio and
others 1997a). A Superose 6 10/300 GL column (Amersham Biosciences, Piscataway,
NJ) on a fast performance liquid chromatography (FPLC) system model 600 (Waters
Chromatography, Milford, MA) was used. One hundred microliter of each serum sample
before the Western diet or 70 µl after the Western diet was loaded into the column.
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Lipoproteins were separated using a buffer containing 0.15 M NaCI, 0.01 M Na2HPO4, 1
mM EDTA (pH 8.0), at a flow rate of 0.5 mL/min. Forty 0.5 ml fractions were collected and
analyzed for cholesterol concentrations as described above, and the cholesterol
concentrations were then divided by the total sample volume loaded into the column for
comparison between the different time points.

Peripheral White Blood Cell Count
Blood smears were prepared from tail blood 12 weeks after bone marrow
transplantation under anesthesia, and subjected to Quick-Dif staining (Vanderbilt
Histochemistry Core Lab). White blood cells were differentiated into lymphocyte,
monocyte, and granulocyte by scoring a minimum of 200 cells under a light microscope.

Analysis of Atherosclerotic Lesions
Sectioning, staining, and quantitative analysis. After 10 weeks on Western diet, mice
were sacrificed and perfused with 20 ml of PBS through the left ventricle. The heart with
proximal aorta attached was embedded in OCT compound and snap-frozen in liquid
nitrogen. All samples were stored at -80 °C before sectioning. Every other 10-µm cross
section was collected starting from the end of the aortic sinus as described (Paigen and
others 1987). Fifteen cryosections from each mouse were stained with Oil Red O (Sigma)
to visualize the lipid contents and counterstained with Mayer’s hematoxylin (Electron
Microscopy Sciences, Hatfield, PA). Quantitative analysis of the lesion area was
performed blindly using a KS300 Imaging Version 3.0 connected to a Carl Zeiss Vision
microscope (Carl Zeiss Vision GmbH, Germany).
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Immunohistochemistry. Serial 5 µm cryosections from proximal aortas were fixed in
acetone at -20 °C for 10 min and stained at 4 °C overnight with either rat anti-mouse
macrophages/monocyte marker MOMA-2 (Accurate Chemical & Scientific Corp.,
Westbury, NY) diluted at 1:1000 in the blocking buffer (5% mouse serum in PBS), or
smooth muscle alpha actin epitope specific rabbit antibody (Lab Vision, Fremont, CA)
diluted at 1:200 in the blocking buffer (5% goat serum in PBS). After briefly rinsing with
PBS, the sections were then incubated with either biotinylated mouse anti-rat IgG2b
antibody (BD Biosciences Pharmingen, San Diego, CA) at 1:200 dilution in the blocking
buffer or biotin labeled goat anti-rabbit IgG polyclonal antibody (BD Biosciences
Pharmingen) at 1:200 dilution at room temperature for 30 min. Following the inactivation
of endogeneous peroxidase in 0.3% H2O2/methanol at room temperature for 30 min, the
sections were incubated with 50 µl streptavidin-HRP complex (BD Biosciences
Pharmingen) at room temperature for 30 min, developed with diaminobenzidine (DAB)
enhanced liquid substrate system (Sigma) at room temperature for 1-2 min, and then
counterstained with methyl green (Vector Labs, Burlingame, CA) at 55 °C for 5 min. After
brief rinsing in PBS, the sections were air-dried and mounted in Permount (Fisher
Scientific). The staining was analyzed using AxioVision 3.1 connected with Axioplan2
imaging microscope (Carl Zeiss Vision GmbH, Germany).

TUNEL staining. An in situ cell death detection POD kit (Roche Applied Science,
Indianapolis, IN) was used with slight modification. Five-micron cryosections were
pretreated with 3% citric acid to eliminate free calcium in order to remove false staining of
calcium-containing matrix vesicles (Kockx and others 1996). Then the sections were fixed
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in 4% paraformaldehyde in PBS, and permeabilized in 0.1% Triton X-100, 0.1% sodium
citrate on ice for 5 min. After incubation with deoxynucleotidyl transferase (5 µl) and
fluorescein-labeled nucleotide mixture (45 µl) in a humidified chamber at 37 °C for 1 h,
sections were treated with anti-fluorescein antibody conjugated with HRP in a dark
humidified chamber at 37 °C for 30 min. The sections were then developed with DAB and
counterstained with methyl green as described above. Four serial sections from each
mouse were stained and the data for each individual mouse were expressed as the
average TUNEL positive cell number per mm2 lesion area. For each group, the data were
expressed as mean±SD.

Statistics
Nonparametric Mann-Whitney test was used to measure the statistical differences in
lesion area. Student’s t test assuming two samples with equal variances was used in
other analyses. P<0.05 was considered to be statistically significant.
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CHAPTER 3
RESULTS

Effect of Bax Knockdown in Macrophage-like Cell Line P388D1
The goal of the present studies is to determine the consequences of macrophage
apoptosis in atherogenesis. Because of the well established and accepted role of Bax in
apoptosis, as well as the specific observations implicating Bax activation in macrophage
apoptosis resulting from free cholesterol loading as well as treatment with oxLDL or
oxysterols, we chose to examine whether Bax deficiency will produce resistance, at least
partially, to oxysterol-induced macrophage apoptosis in vitro by inhibiting Bax expression
in cultured macrophage-like cell line P388D1 using siRNA. The single-stranded SiBax
transcript contains 20-nucleotide complementary sequences (bold): 5’-ACTGGTGCTCA
AGGCCCTGTTCAAGAGACAGGGCCTTGAGCACCAGTTTTTTT-3’. It forms a hairpin
structure with the complementary sequence in the stem region. Upon cleavage by Dicer,
the stem region will then form a functional double-straned siRNA, which would be
expected to bind and degrade the target Bax mRNA. The double-stranded small RNA
formed by the cleavage of R-Bax transcript (5’-ACCGCTCGAGCGTGCTAGTTTCAAG
AGAACTAGCACGCTCGAGCGGTTTTTTT-3’) is not expected to interfere with Bax
expression due to its sequence nonspecificity.
Stably transfected P388D1 cells were selected as described in Materials and
Methods. Several G418 resistant clones, three transfected with SiBax (S1, 7, 14) and two
transfected with R-Bax (R1, 2), were selected. Caspase 3 activity was examined after a
16-h treatment with 10 µg/ml 25-OHC. The increase of caspase 3 activity was
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significantly lower in clone S1, 7, and 14, compared to that in clone R1 and R2, indicating

Total Caspase 3 Activity (x1000 FLUs)

decreased apoptotic activities in clone S1, 7, and 14 (Fig 5).
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Figure 5 Caspase 3 activity assay in R-Bax and SiBax stably transfected clones. Cells
were treated with 10 µg/ml 25-OHC for 16 h. Each treatment was performed in triplicate,
and data were presented as mean±S.D. *P< 0.05 compared to R1 treated with 25-OHC.

Suppression of Bax in P388D1 Cells Transfected with SiBax
Clones S1 and R1 were selected based upon the caspase 3 assay results and
examined for the suppression of Bax protein by immunoblotting (Fig 6). The expression of
Bax was significantly reduced in clone S1 comparing with that in clone R1. As expected,
suppression of Bax did not affect the expression of other proteins such as Akt/ protein
kinase B or Bak in either of these clones, which indicates the high specificity of the insert
sequence in SiBax.
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Figure 6 Suppresion of Bax in P388D1 cells by siRNA. Whole cell lysates from clone R1
and S1 were resolved by SDS-Page on 4-12% NuPage gel, and probed for Bax and Akt
(A) or for Bax and Bak (B). Neither Akt nor Bak expression level was affected in clone S1
with significant Bax suppression comparing to that in clone R1.

Reduced Caspase 3 Activity in P388D1 Cells with Bax Suppression
Because the G418 resistant SiBax clones were only partially resistant to the induction
of caspase activity by 25-OHC, clone S1 was further selected by incubating with 10 µg/ml
25-OHC for 68 h. The surviving cells were expanded and assayed for the caspase 3
activity assay. Clone R1 and the oxysterol selected clone S1 were cultured in medium
containing increasing amounts of 25-OHC for 16 h. Control cells received an equal
amount of vehicle only (ethanol). Caspase 3 activity was determined as described in
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Materials and Methods. Induction of apoptosis by 25-OHC was greatly attenuated in
clone S1 comparing with that in clone R1 regardless of the normal expression of Bak (Fig
7). About 5.5 fold increase was observed in R1 cells treated with 20 µg/ml 25-OHC,

Fold Induction of Caspase 3 Activity

however, almost no induction was found in S1 cells under the same treatment.
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Figure 7 Caspase 3 activity assay in clone R1 and S1. After 68-hour selction in 10 µg/ml
25-OHC, cells were treated for 16 h with increasing amounts of 25-OHC. Each treatment
was done in triplicate, and the data presented as the mean ± S.D. of the fold increase in
caspase 3 activity compared to the untreated cells.

Bax Deficient Mouse Peritoneal Macrophages Display Reduced Levels of Apoptosis in
vitro upon Stimulation by Oxysterols or Staurosporine
Our siRNA experiments successfully demonstrated that suppression of Bax leads to
decreased apoptotic activity in response to 25-OHC in P388D1 cells, a mouse
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lymphoblast cell line with macrophage-like morphololgy. In order to directly examine the
impact of Bax deficiency on apoptosis in mouse macrophages, peritoneal macrophages
were isolated from WT C57BL6 and Bax knockout mice. The caspase 3 activity was
assayed after 12 h treatment with 10 µg/ml 7-ketocholesterol, one of the major cytotoxic
components of oxLDL (Panini and Sinensky 2001). The caspase 3 activity was
significantly lower in Bax null macrophages treated with 7-ketocholesterol compared to
that in WT macrophages treated with 7-ketocholesterol (P<0.05) (Fig 8A).
To further determine the effect of Bax deficiency on apoptosis, mouse peritoneal
macrophages were treated with either 25-OHC or staurosporine and subjected to TUNEL
staining, an alternative technique to identify apoptotic cells. Consistent with the results
from caspase 3 activity assay, Bax null macrophages also showed less TUNEL positive
cells compared with the WT cells after treatment with either 25-OHC or staurosporine (Fig
8B, P<0.05). Therefore, consistent with prior studies with Bax knockdown P388D1 cells
(Fig 5 and 7), Bax null mouse peritoneal macrophages are also partially resistant to
apoptosis induced by oxysterols. They are also partially resistant to staurosporine, which
also acts through the mitochondrial pathway. This is consistent with previous report that
Bax deficient mouse embryonic fibroblast cells shows partial resistance to the apoptosis
induction by staurosporine (Wei and others 2001).
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A: Caspase 3 activity assay
1400

WT

1200

Bax-/-

RFU (X100)

1000

*

800
600
400

*

200
0
0

10 µg/ml 7-KC

% of TUNEL positive cells

B: TUNEL assay
18

WT

16

Bax-/-

14

*

12
10
8
6

*

4
2
0
Control

25-OHC 10 µg/ml

STS 0.5 µg/ml

Figure 8 Bax deficient mouse peritoneal macrophages display reduced apoptosis in vitro.
A: Caspase 3 activity assay after 12 h treatment with 7-ketocholesterol (7-KC). Relative
fluorescent unit (RFU) was normalized to protein concentration of the sample. Data
represent mean±SD of three independent experiments. B: TUNEL staining after the
treatment with 25-OHC for 40 h or staurosporine (STS) for 21 h. Each bar represents the
mean value of 10 viewfields under 400x magnification. Data represent the mean±SD,
*P<0.05 compared to the WT group.
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Complete Reconstitution of LDLR-/- Mice with WT or Bax-/- Bone Marrow
As expected, our in vitro studies show that Bax deficiency leads to significantly
reduced apoptosis in mouse peritoneal macrophages in response to agents that activate
the mitochondrial death pathway. To investigate the consequences of macrophage
apoptosis in the development of atherosclerosis in vivo, 8-week old LDLR-/- mice (male,
n=14 in each group) were lethally irradiated and transplanted with 5x106 bone marrow
cells isolated from WT or Bax null donor mice (male). The reconstitution of recipient mice
with donor bone marrow-derived hematopoietic cells was determined by immunoblotting
13 weeks post bone marrow transplantation. Bax protein was detected in the peritoneal
macrophages isolated from the WT group, but not in those from the Bax-/- group (Fig 9).
WTÆLDLR-/- Bax-/-ÆLDLR-/Bax
β-actin

Figure 9 Immunoblotting to examine the chimerism of reconstitution. Whole cell lysates
were prepared from peritoneal macrophages isolated from four recipient mice randomly
chosen from each group 13 wks after bone marrow transplantation and separated by
SDS-PAGE. Immunoblotting was performed as described above. The same blot was
stripped and reprobed for β-actin as the loading control.

The level of reconstitution was also determined by PCR of the LDLR gene as both sets
of donor bone marrow cells were LDLR positive. Consistently, 8 weeks after the bone
marrow transplantation, a 400 bp PCR product of the wild type LDLR gene was detected
in the genomic DNA extracted from the whole blood of all mice from both groups. In
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addition, the 800 bp PCR product of the mutant LDLR gene in both groups was below the
detectable level after 30 PCR cycles indicating a complete reconstitution of the recipient
hematopoietic cells by the donor bone marrow cells (Fig 10).

Ladder WT Bax-/- ÆLDLR-/-

WT

WT ÆLDLR-/-

1000 bp
500 bp

WT LDLR
400 bp

Ladder

Bax-/- ÆLDLR-/- LL-/-

WTÆLDLR-/Ko LDLR
800 bp

1000 bp
500 bp

Figure 10 PCR assay to examine the chimerism of reconstitution. DNA samples from 6
mice in the Bax-/- transplantation group and 7 mice in the WT transplantation group were
subjected to PCR assay using primers either for the WT LDLR gene (400 bp product) or
the knockout (Ko) LDLR gene (800 bp product). For detecting WT LDLR gene, genomic
DNA from WT C57BL6 mouse was used as the positive control (WT). For detecting Ko
LDLR gene, genomic DNA from LDLR-/- mouse was used as the positive control (LL-/-).

Bax Deficiency in Bone Marrow Derived Cells Does not Affect the Plasma Cholesterol
and Triglyceride Levels
Macrophages, native or bone marrow graft derived, express a variety of proteins that
affect lipoprotein clearance and cholesterol metabolism through a number of different
pathways, and they have been shown to influence the progression of atherosclerosis
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(Linton and Fazio 2001; Linton and Fazio 2003). To examine whether Bax deficiency in
bone marrow derived cells, especial macrophages, would affect cholesterol metabolism
in the host, the plasma lipid parameters were assessed. Plasma samples were collected
before the start of Western diet as the baseline and every 4 weeks thereafter. As shown
below, Bax deficiency in macrophages did not affect the plasma cholesterol (Fig 11A) and
triglyceride levels (Fig 11B). Both groups displayed a gradual increase in the plasma
cholesterol level as time went by, from ~200 mg/dl before Western diet to ~600-700 mg/dl
8 wks after. The changes in plasma triglyceride levels were less dramatic than those
observed in plasma cholesterol. In both groups, the average plasma triglyceride level was
around 80 mg/dl before BMT and increased to 110 mg/dl 8 wks after BMT. This was
expected because LDL is the major cholesterol carrier in the plasma as shown in Table 1.
As a result, the accumulation of LDL in the plasma will mainly affect the cholesterol
concentration in the plasma.
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Figure 11 Plasma total cholesterol (A) and triglyceride (B) levels. Data were collected
before (baseline) and every 4 wks after the beginning of Western diet. P>0.05 compared
to WT group.

Bax Deficiency in Bone Marrow Derived Cells Has no Influence on Plasma Lipoprotein
Profile
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Elevated plasma cholesterol concentrations, especial LDL concentrations, are
strongly correlated with atherosclerotic disease. Shifting between different serum
lipoprotein particles can also significantly affect the incidence of coronary heart disease
and the rate of progression of coronary lesions (Goldstein and Brown 1979; Hobbs and
others 1992). To examine whether Bax deficiency in bone marrow derived cells would
affect the plasma lipoprotein profile, plasma samples from both the control and Bax-/groups were analysed by FPLC before and every 4 wks after the beginning of Western
diet. Before Western diet, almost half of the lipoprotein particles (25 mg/dl) were
anti-atherogenic HDL in both groups, leaving the rest mainly in LDL (20 mg/dl) with very
low level of VLDL (<5 mg/dl). After 4 weeks of Western diet, both VLDL and LDL fractions
increased dramatically with the peak value between 50-60 mg/dl. With the profile shifting
towards the non-HDL fractions, the plasma lipoproteins became more atherogenic
(Breslow 1996). After another 4 weeks of Western diet, the peak value of LDL fraction
remained at around 60 mg/dl, while the peak value of VLDL accelerated to over 70 mg/dl.
Western diet did not affect the HDL fraction, and its peak value remained at the same
level as that before the diet. However, as shown below, no differences were found
between the two groups (Fig 12), indicating Bax deficiency in bone marrow derived cells
does not affect the lipoprotein clearance, and consequently, the shift in lipoprotein profiles
induced by Western diet.
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Figure 12 Plasma lipoprotein profiles obtained by FPLC. Plasma samples from individual
mice were analysed. The results shown are representative curves from each group.
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Bax Deficiency in Bone Marrow Derived Cells Does not Affect Peripheral Lymphocyte
Population
Bax deficient mice have been reported to have selective hyperplasia of lymphoid
tissues (Knudson and others 1995). The influence of lymphocytes on atherosclerosis has
been reported by many groups (Daugherty and others 1997; Major and others 2002;
Pinderski and others 2002; Tanigawa and others 2003). To determine whether Bax
deficiency in bone marrow graft would increase the peripheral lymphocyte number, we
examined the peripheral leukocytes in the blood smears obtained from all recipient mice
by Quick-dif staining 12 weeks after bone marrow transplantation. Differential white blood
cell counts revealed no differences in the peripheral lymphocyte populations between two
groups (P>0.05). In the control group, about 81.3±2.9 % peripheral leukocytes were
lymphocytes, compared to 79.5±8.7 % in the Bax-/- group. Thus, Bax deficiency in bone
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marrow derived cells did not affect the peripheral lymphocyte population (Fig 13).
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Figure 13 Peripheral lymphocyte counts 12 weeks after bone marrow transplantation. No
differences were found between the WT and Bax-/- groups. P>0.05.
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Bax Deficiency in Macrophages Accelerates the Development of Atherosclerosis
To examine the influence of Bax deficiency on the development of atherosclerosis, all
recipient mice were sacrificed after 10 weeks on a Western diet. The atherosclerotic
lesions in the proximal aortas were stained with Oil Red O. Quantitative analysis of the
extent of atherosclerosis revealed a 49.2% increase in the mean cross sectional lesion
area (µm2±SEM) in the proximal aortas of Bax-/- group (233,800±20,489 µm2) compared
with that in the control group (156,700±20,243 µm2) (Fig 14, P=0.0259). Thus, LDLR-/mice reconstituted with bone marrow null for Bax display significantly higher degree of
atherosclerotic lesion formation.
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Figure 14 Lesion area quantitation in cross sections of proximal aortas after 10 weeks on
Western diet. A 49.2% increase in the mean cross sectional lesion area was found in the
Bax-/- group compared to that in the WT group. Each data point represents the mean
lesion area per cross section of 15 sections per mouse, line represents the mean value of
each group, n=14 mice per group, P=0.0259 by nonparametric Mann-Whitney test.
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To further characterize the atherosclerotic plaques, macrophages and SMCs in serial
cross sections of the proximal aortas from both groups were stained with cell type specific
antibodies (Fig 15). Immunocytochemical analysis demonstrated that the lesions
contained predominantly macrophage-derived foam cells. Lesions were classified into
two types based on the prior literature (van Vlijmen and others 1994; Breslow 1996;
Kanters and others 2003): early lesions mainly composed of macrophage derived foam
cells and advanced lesions characterized by the presence of SMCs and collagen in the
cap area. Interestingly, 31% of the lesions in the Bax-/- group, compared to only 17% in
the control group, were advanced lesions with fibrous caps. These fibrous plaques from
both groups were larger in size compared to those without SMC staining in the cap region,
indicating they were in a more advanced stage. These lesions often contained necrotic
cores while observing under higher magnification. Taken together, our studies show that
Bax deficiency in bone marrow derived cells not only stimulates the formation of
atherosclerosis in LDLR null mice fed a Western diet but may also accelerate the
progression to more advanced lesions as well.
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Figure 15 Immunostaining for macrophages in the lesion (A,C) and SMCs in the arterial
wall and lesion cap area (B,D) in serial cross sections from proximal aorta. A,B: serial
cross sections from WT group with a smaller lesion consisting mainly of macrophage
derived foam cells. C,D: serial cross sections from Bax-/- group showing a larger lesion
consisting of both macrophage-derived foam cells and SMCs in the cap region. Scale bar
represents 200 µm.

Deficiency of Macrophage Bax Leads to Reduced Apoptosis in Atherosclerotic Lesions
As described in figure 8, Bax null macrophages display reduced levels of apoptosis in
vitro. To investigate whether the increased lesion area in the Bax null transplantation
group was associated with decreased apoptotic activity in vivo, modified TUNEL was
carried out on cross sections of proximal aortas. The majority of apoptotic cells in the
lesions were macrophages. Consistent with the proposed role for Bax in macrophage
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apoptosis, the number of apoptotic macrophages was decreased by 53% (P<0.05) in the
Bax-/- group (15.3±9.9 per mm2) compared to that of the control group (32.5±10.8 per
mm2, Fig 16). Thus, the increased average lesion size (~50%) of Bax-/- group is
associated with the reduced apoptotic activity (53%) in the lesional macrophages in this
group.
Interestingly, the SMCs in the proximal aorta from the Bax-/- group also had reduced
apoptosis compared to those from the WT group. About 8.6±6.3 apoptotic SMCs per mm2
were observed in the Bax-/- group, while 25.6±10.3 apoptotic SMCs per mm2 were
observed in the control group (Fig 16C, P<0.05). This difference could be due to the
altered interactions between macrophages and SMCs in the Bax-/- group, or the
origination of SMCs from Bax-/- bone marrow. This will be discussed in greater detail in
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Figure 16 In situ TUNEL staining in proximal aorta sections. Sections from the control
group (A) and the Bax-/- group (B) were labeled as described above and counterstained
with methyl green. Arrows indicate TUNEL positive nuclei (brown), Scale bar represents
200 µm. C: Quantitation of TUNEL positive macrophages and SMCs per mm2 lesion area,
n=14, *P<0.05 compared to WT group.
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CHAPTER 4
DISCUSSION

Macrophages are one of the most important cell types in atherosclerotic lesions, not
only because the lesions are mainly composed of macrophages, as observed in figure 15,
but also because macrophages can generate a variety of protein molecules (such as
apoE, apoAl, and ACAT etc.) that affect lipoprotein clearance and cholesterol
metabolism, which are two significant factors influencing the progression of
atherosclerosis.
The evidence of apoptosis in atherosclerotic lesions has been broadly reported, and
apoptosis mainly happens in the macrophage population in the lesion (Ball and others
1995; Lusis 2000). Possible causes of macrophage death in atherosclerotic lesions
include exposure to oxidized lipoproteins, cholesterol-induced cytotoxicity (Warner and
others 1995; Tabas and others 1996), growth factor deprivation (Chin and others 1999),
and exposure to other arterial wall factors such as inflammatory cytokines and nitric oxide
(Mitchinson and others 1996; Lopez-Collazo and others 1998). However, it remains
unclear whether the apoptotic events in the lesion will prevent or facilitate the
development of atherosclerosis due to lack of direct evidences.
In the current study, our goal was to determine the influence of macrophage apoptosis
in atherogenesis, which was achieved through two steps: 1) we chose one of the
proapoptotic proteins - Bax as our experimental target and examined the effect of Bax
knockdown on apoptosis induction in macrophages; 2) we reconstituted the LDLR-/mice, an atherogenesis-prone model, with bone marrow isolated from either WT or Bax
null mice, and assessed the development of atherosclerosis in both groups.
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Bax was chosen because of the well accepted role of Bax in the mitochondrial
apoptosis pathway, as well as the specific observations implicating Bax activation in
association with macrophage apoptosis resulting from free cholesterol loading, and
oxLDL or oxysterol treatment (Yao and Tabas 2000; Yao and Tabas 2001; Rusinol and
others 2004). Although Bax deficient mouse embryonic fibroblast cells have been shown
to be partially resistant to the induction of apoptosis by staurosporine (Wei and others
2001), no observations have been reported in terms of the effect of Bax deficiency on
apoptosis induction in macrophages. To seek direct answers, we chose to use 1) a
macrophage-like cell line P388D1 with Bax expression suppressed by specific siRNA,
and 2) mouse peritoneal macrophages isolated from Bax deficient mice. Both cell types
showed decreased apoptotic activities upon the stimulation by oxysterols compared to
control cells (Fig 7,8), demonstrating that Bax deficiency in macrophages provided partial
resistance to apoptosis induction in vitro. Partial resistance was expected because the
functions of Bax have been shown to be redundant with Bak and only cells lacking both
Bax and Bak are totally defective in the mitochondrial pathway (Wei and others 2001).
The reconstitution of LDLR-/- mice with Bax null bone marrow resulted in a significant
increase in mean lesion area as compared with the mice reconstituted with wild type bone
marrow (Fig 14,15). As expected, fewer apoptotic macrophages were found in the Bax-/group (Fig 16), which was not only consistent with our in vitro experimental results, but
also consistent with our hypothesis that the increase in lesion size is due to decreased
apoptotic activity in the macrophage. In addition, higher numbers of advanced lesions
with fibrous caps were found in the Bax-/- group (Fig 15). Our data demonstrate that
macrophage apoptosis plays a protective role in the development of atherosclerosis. This
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is the first report that directly demonstrates a link between the mitochondrial apoptotic
pathway and atherogenesis.
Induction of apoptosis by oxysterol is mediated via the mitochondrial death pathway
and most probably occurs within atherosclerotic lesions (Panini and Sinensky 2001).
However, because of the central role that Bax plays in the mitochondrial apoptosis
pathway, the reduction of apoptosis in atherosclerosis lesions observed in mice
transplanted with Bax-/- bone marrow would be expected for a broad spectrum of
apoptotic inducers. For this reason, our observations are more relevant to the role of
macrophage apoptosis in atherogenesis than to the role of any specific physiological
apoptotic inducer.
Some prior studies have attempted to determine the role of apoptosis in
atherogenesis by means of p53 null mice. Macrophages deficient in the tumor suppresser
protein p53 have been reported to enhance atherosclerosis in apoE*3-Leiden transgenic
mice, which was correlated with a decrease in apoptosis in the p53 deficient mice (van
Vlijmen and others 2001). Increased atherosclerosis has also been reported in another
study using p53-/-apoE-/- mice, although the authors did not find significant change in
apoptotic cell numbers but, rather, an increase in cell proliferation (Guevara and others
1999). These contradictory results probably reflect the multiple functions of p53 which
acts to integrate a number of cellular signals to regulate either cell cycle arrest or
apoptosis rather than acting as a specific regulator of the mitochondrial death pathway
(Bennett 1999; Haupt and others 2003). In contrast, Bax deficiency directly affects the
mitochondrial pathway, which can be stimulated by various signals including the
activation of p53.
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In another study of the role of apoptosis in atherosclerosis, the bcl-xL expression, one
of the anti-apoptotic Bcl-2 family members, in neointimal cells in carotid arteries of rabbits
was inhibited by transfection with anti-bcl-x antisense oligonucleotides (Pollman and
others 1998). The reduced apoptosis induction within intimal cells was observed, as well
as an acute regression of lesions in carotid arteries, which is consistent with the results of
our study. However, under these experimental conditions, the cell types that took up the
antisense oligonucleotides were uncertain. In contrast, the current study is clearly
focused on lesion macrophages derived from Bax null donor bone marrow. Our results
more specifically demonstrate the effect of the mitochondrial apoptotic pathway in lesion
macrophages on the development of atherosclerosis.
Bcl-2 family proteins also affect the survival of lymphocytes (Cory 1995; Cheng and
others 2004). Bax deficient mice have been reported to have selective hyperplasia of
lymphoid tissues (Knudson and others 1995). The influence of lymphocytes on the
development of atherosclerosis, a chronic inflammatory disease, has been reported by
many groups (Daugherty and others 1997; Major and others 2002; Pinderski and others
2002; Tanigawa and others 2003). In searching for any additional mechanistic
explanation for increased lesion area in mice transplanted with Bax-/- bone marrow, we
examined the peripheral leukocytes in all recipient mice by Quick-dif staining. No
differences were found in the peripheral lymphocyte content between the two groups.
However, increased inflammation in Bax-/- group cannot be excluded since lesions in this
group contain higher number of macrophages, one of the mediators of inflammatory
response in atherosclerotic lesions (Libby 2002; Linton and Fazio 2003), compared to
lesions in the WT group.
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Although the reduced apoptotic activity in lesional macrophages provides an
explanation for the increased atherosclerotic lesion size, there are a number of other
pro-atherogenic aspects of lesion macrophages. Mice deficient in both macrophage
colony-stimulating factor (MCSF) and apoE (op/apoE) have smaller proximal aortic
lesions at earlier stages of lesion progression and decreased blood monocyte differentials
(Smith and others 1995). Consistent with this observation, intraperitoneal administration
of antibody for the MCSF receptor prevents the initial events of atherogenesis (Murayama
and others 1999). Therefore, a lowered level of apoptosis in Bax deficient macrophages
would also be expected to be pro-atherogenic by certain macrophage dependent
processes such as increased number and/or functions of monocyte-derived
macrophages, increased growth factor production, cell proliferation, or foam cell
accumulation (Linton and Fazio 2003).
Recently, Chlamydia pneumoniae has been reported to inhibit apoptosis in THP-1
cells (Carratelli and others 2002) and HeLa cells (Fischer and others 2001). Reduction of
cytochrome c release was characterized in Chlamydia pneumoniae infected Hela cells.
Human CMV immediate-early proteins have also been reported to inhibit apoptosis
occurence in the coronary artery smooth muscle cells by antagonizing the function of p53
protein. The reduced apoptotic activity in vascular cells following the viral/bacterial
infection thus may provide an explanation for the pro-atherogenic roles of Chlamydia
pneumoniae and CMV in humans, which is consistent with our demonstration that
macrophage apoptosis is an anti-atherogenic event.
Our observation that mice reconstituted with Bax null bone marrow have decreased
SMC apoptosis is also of interest. Intermediate plaques are often covered by a fibrous
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cap consisting of SMCs and interstitial collagen fibers synthesized by SMCs. Loss of
SMCs in the cap area will lead to a decrease in the production of the interstitial collagen
fibers and, consequently, thinning of the fibrous cap. Plaque rupture occurs when the
mechanical stresses in the fibrous cap exceed a critical level that the cap tissue can
withstand. The interaction between macrophages and SMCs has long been controversial.
For example, platelet-derived growth factor (PDGF) produced by macrophages has been
shown to induce the migration and proliferation of SMCs (Shimokado and others 1988;
Ross and others 1990; Shen and others 2001). However, a number of other studies have
demonstrated that macrophage-derived factors could kill SMCs (Boyle and others 2002;
Seshiah and others 2002; Boyle and others 2003). Our data showed increased SMC
content in the cap and shoulder region of the lesions and reduced SMC apoptosis in the
lesions of LDLR-/- mice reconstituted with Bax null bone marrow. Although the origin of
these SMCs has not yet determined, the possibility that these SMCs are derived from Bax
deficient bone marrow can not be excluded according to the recent reports (Sata and
others 2002; Caplice and others 2003). The increased SMC content in the lesions of the
Bax-/- group may also be due to a stimulation of SMC migration caused by Bax deficiency
in bone marrow derived macrophages or lymphocytes. The mechanism by which this may
occur is unclear at present. Because the increased SMCs and extracellular matrix content
in fibrous plaque have been suggested to be critical factors in increasing plaque stability
in human atherosclerosis (Libby and Aikawa 2002), it will be very interesting to investigate
whether apoptosis inhibition in vascular SMCs could benefit the plaque stability in
atherosclerosis.
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In summary, our studies show that Bax deficiency in macrophages leads to reduced
apoptosis both in vitro and in vivo. In atherosclerotic lesions, the reduced apoptotic
activity in macrophages due to Bax deficiency promotes the development of
atherosclerosis in LDLR null mice on a Western diet. Analogous to other
apoptosis-associated diseases, such as cancer, autoimmune disease, and certain viral
infections, failure to undergo apoptosis in atherosclerotic lesions leads to the excessive
accumulation of cells, indicating that macrophage apoptosis provides a critical
self-defense mechanism in suppressing atherosclerosis..
Mitochondria-targeting pro-apoptotic drugs have been under broad development for a
wide range of applications, from cancer chemotherapy, HIV, to organ transplantation
(Zangemeister-Wittke and Ziegler 1998; Morisaki and Katano 2003). Our data indicate
that the mitochondrial apoptosis pathway in vascular macrophages may be an attractive
target for the prevention and treatment of atherosclerosis.
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